PRO-MSH-001
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Key Facts
About ProdIgY Biotech
ProdIgY Biotech is developing first-in-class, orally administered IgY antibody therapies that target the gut-liver axis to treat serious liver diseases, starting with alcohol-associated hepatitis (AH). Its lead candidate, PRO-AH-001, is designed to selectively neutralize the bacterial toxin cytolysin and its producer, addressing a root cause of disease progression with a non-systemic mechanism. Founded in 2018 and based in San Diego, the company is privately held and pre-revenue, with a preclinical pipeline that also includes programs for Primary Sclerosing Cholangitis (PSC) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). The technology is supported by peer-reviewed research, including a 2023 cover publication in Hepatology.
View full company profileTherapeutic Areas
Other Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs
| Drug | Company | Phase |
|---|---|---|
| NGM831 (MK-3655) | NGM Biopharmaceuticals | Phase 2b |
| Pegozafermin (BIO89-100) | 89bio | Phase 3 |
| Icosabutate | NorthSea Therapeutics | Phase 3 |
| Oxy210 | MAX BioPharma | Preclinical |
| NA-941 | Biomed | Phase 2A |
| Undisclosed MASH Program | Syndya Therapeutics | Discovery |
| Partnered Program | Cellarity | Pre-clinical |
| Lanifibranor | Hepalys | Phase 1 |
| IW-601 | ImmuneWalk Therapeutics | Preclinical |
| ION224 (IONIS-DGAT2Rx) | Ionis Pharmaceuticals | Phase 2b |
| ALG-055009 | Aligos Therapeutics | Phase 2 |
| CM-101 | Chemomab Therapeutics | Phase 2a |